The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
| | |
PRELIMINARY PROSPECTUS | | SUBJECT TO COMPLETION, DATED NOVEMBER 5, 2021 |
$110,000,000
Atlas Growth Acquisition Limited
11,000,000 Units
Atlas Growth Acquisition Limited is a blank check company newly incorporated as a Cayman Islands exempted company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we currently intend to focus our efforts in Asia with an emphasis on sourcing opportunities that are in the healthcare, consumer technology and technology, media and telecommunications industries. We do not have any specific business combination under consideration and we have not (nor has anyone on our behalf), directly or indirectly, contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to such a transaction with our company.
This is an initial public offering of our securities. We are offering 11,000,000 units at an offering price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half (1/2) of one redeemable warrant, which we refer to throughout this prospectus as the “public warrants.” Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per full share, subject to adjustment as described in this prospectus. Each warrant will become exercisable 30 days after the completion of an initial business combination, and will expire on the fifth anniversary of our completion of an initial business combination, or earlier upon redemption or liquidation. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. We will not issue fractional shares and warrants may be exercised only for a whole number of shares.
We have also granted the underwriters, a 45-day option to purchase up to an additional 1,650,000 units (over and above the 11,000,000 units referred to above) solely to cover over-allotments, if any.
We will provide our public shareholders with the opportunity to redeem their Class A ordinary shares upon the consummation of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account described below, including interest (net of taxes payable), divided by the number of then issued and outstanding Class A ordinary shares that were sold as part of the units in this offering, which we refer to as our “public shares.”
We have 18 months from the closing of this offering to consummate our initial business combination. However, if we anticipate that we may not be able to consummate our initial business combination within 18 months, we may, but are not obligated to, extend the period of time to consummate a business combination two times by an additional three months each time (for a total of up to 24 months to complete a business combination) as described in this prospectus. If we are unable to consummate our initial business combination within the above time period, we will distribute the aggregate amount then on deposit in the trust account, net of taxes payable, and less up to $50,000 of interest to pay liquidation expenses, pro rata to our public shareholders by way of the redemption of their shares and to cease all operations except for the purposes of winding up of our affairs, as further described herein. In such event, the warrants will expire and be worthless.
We have issued to our sponsor, Atlas Growth Holdings Limited, and certain of its affiliates (collectively, our “initial shareholders”) an aggregate of 3,162,500 Class B ordinary shares (including up to an aggregate of 412,500 Class B ordinary shares subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part) in exchange for a capital contribution of $25,000, or approximately $0.008 per share. The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination on a one-for-one basis, subject to the adjustments described herein. The holders of our Class B ordinary shares will have the right to elect all of our directors prior to our initial business combination and the holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time.
In addition, our sponsor has committed to purchase from us an aggregate of 5,300,000 warrants (or 5,795,000 warrants if the over-allotment option is exercised in full) (the “private warrants”) at a price of $1.00 per warrant in a private placement for an aggregate purchase price of $5,300,000 (or $5,795,000 if the over-allotment option is exercised in full). Each private warrant will be identical to the warrants included in the units sold in this offering, except as described in this prospectus. The private warrants will be sold in a private placement that will close simultaneously with the closing of this offering, including the over-allotment option, as applicable.
There is presently no public market for our units, Class A ordinary shares or warrants. We have applied to have our units listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “[ATLAU]” on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq. Once the securities comprising the units begin separate trading as described in this prospectus, we expect the Class A ordinary shares and warrants will be traded on Nasdaq under the symbols “[ATLA],” and “[ATLAW],” respectively. We cannot assure you that our securities will be approved for listing and, if approved, will continue to be listed on Nasdaq after this offering.
Although our efforts to identify a prospective target business will not be limited to a particular industry or geographic location, we currently intend to focus our efforts in Asia and may acquire a company based in or with the majority of its operations in China. If we choose to acquire a China-based company, we will be subject to risks associated with acquiring a company that does business in China, including being subject to various risks related to PRC laws and regulations which are sometimes vague and uncertain. Recently, the Chinese government initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. Since these statements and regulatory actions are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and the potential impact such modified or new laws and regulations will have on our daily business operation post-business combination and our ability to accept foreign investments and to list on a U.S. or other foreign exchange. To the extent that the Chinese government intervenes or influences our operations post-business combination at any time or exerts more control over offerings conducted overseas and foreign investment in China-based issuers, our operations and/or the value of our Class A ordinary shares may be materially affected. Additionally, the governmental and regulatory interference could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.
Moreover, If we consummate our business combination with a China- based company, we will conduct our operations in China primarily through one or more subsidiaries and/or variable interest entities (“VIEs”) in China. As a result, although other means may be available for us to obtain financing at the holding company level, Atlas Growth Acquisition Limited’s ability to pay dividends to its shareholders and to service any debt it may incur may depend upon dividends paid by our PRC subsidiaries and/or license and service fees paid by our PRC consolidated affiliated entities. If any of our future subsidiaries incurs debt on its own in the future, the instruments governing such debt may restrict the subsidiary’s ability to pay dividends to Atlas Growth Acquisition Limited. In addition, our future PRC subsidiaries and variable interest entities will be required to make appropriations to certain statutory reserve funds, which are not distributable as cash dividends except in the event of a solvent liquidation of the companies. Current PRC regulations permit indirect PRC subsidiaries to pay dividends to their parent only out of their accumulated profits, if any, determined in accordance with Chinese accounting standards and regulations. In addition, companies in China are